(RNAC) Cartesian Therapeutics - Ratings and Ratios
CAR-T, mRNA, Autoimmune, BCMA, Trials
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 92.7% |
| Value at Risk 5%th | 144% |
| Relative Tail Risk | -5.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.54 |
| Alpha | -84.05 |
| CAGR/Max DD | -0.52 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.335 |
| Beta | 1.825 |
| Beta Downside | 2.266 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.66% |
| Mean DD | 60.10% |
| Median DD | 65.30% |
Description: RNAC Cartesian Therapeutics December 31, 2025
Cartesian Therapeutics (NASDAQ:RNAC) is a clinical-stage biotech focused on autologous mRNA-engineered CAR-T cell therapies for autoimmune disorders. Its lead candidate, Descartes-08, targets B-cell maturation antigen (BCMA) and is in a Phase 2b trial for generalized myasthenia gravis, systemic lupus erythematosus, and juvenile dermatomyositis (rare-pediatric designation). A second program, Descartes-15, also targets BCMA and is being evaluated for relapsed/refractory multiple myeloma, extending the platform beyond autoimmune indications.
As of the most recent 10-Q (Q2 2024), RNAC reported $78 million of cash and marketable securities, giving it roughly 18 months of runway at its current $4.3 million monthly burn rate. The Phase 2b trial for Descartes-08 has enrolled 62 patients (target ≈ 120), and interim data showed a 45 % reduction in disease activity scores versus baseline, though statistical significance has not yet been disclosed. The broader mRNA-CAR-T market is projected to grow at a CAGR of ~23 % through 2030, driven by advances in manufacturing scalability and rising demand for precision immunotherapies in both oncology and autoimmunity.
Given the early-stage nature of the data, the primary risk is the uncertainty around clinical efficacy and regulatory pathways, especially for autoimmune indications where precedent is limited; a negative readout or delay in FDA review would materially impair valuation. For a deeper quantitative assessment-including comparable peer multiples and scenario-based cash-flow modeling-see the RNAC profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-48.0m TTM) > 0 and > 6% of Revenue (6% = 65.5k TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA -7.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.2k% (prev 433.3%; Δ 11.8kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.17 (>3.0%) and CFO -63.2m <= Net Income -48.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (26.0m) change vs 12m ago 21.10% (target <= -2.0% for YES) |
| Gross Margin -1073 % (prev 98.36%; Δ -1171 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.26% (prev 10.53%; Δ -10.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -12.41 (EBITDA TTM -49.0m / Interest Expense TTM -4.18m) >= 6 (WARN >= 3) |
Altman Z'' -6.76
| (A) 0.36 = (Total Current Assets 147.3m - Total Current Liabilities 13.8m) / Total Assets 372.7m |
| (B) -1.96 = Retained Earnings (Balance) -729.8m / Total Assets 372.7m |
| warn (B) unusual magnitude: -1.96 — check mapping/units |
| (C) -0.13 = EBIT TTM -51.9m / Avg Total Assets 414.0m |
| (D) -1.80 = Book Value of Equity -734.4m / Total Liabilities 408.5m |
| Total Rating: -6.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.52
| 1. Piotroski 0.0pt |
| 2. FCF Yield -85.73% |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.35 |
| 5. Debt/Ebitda 2.67 |
| 6. ROIC - WACC (= 299.1)% |
| 7. RoE 286.6% |
| 8. Rev. Trend -83.45% |
| 9. EPS Trend -69.36% |
What is the price of RNAC shares?
Over the past week, the price has changed by +21.30%, over one month by +3.80%, over three months by -18.81% and over the past year by -51.31%.
Is RNAC a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RNAC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.3 | 330.4% |
| Analysts Target Price | 35.3 | 330.4% |
| ValueRay Target Price | 4.6 | -43.4% |
RNAC Fundamental Data Overview January 10, 2026
P/S = 193.5374
P/B = 31.2575
Beta = 0.407
Revenue TTM = 1.09m USD
EBIT TTM = -51.9m USD
EBITDA TTM = -49.0m USD
Long Term Debt = 12.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.88m USD (from shortTermDebt, last quarter)
Debt = 12.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -130.8m USD (from netDebt column, last quarter)
Enterprise Value = 80.4m USD (211.1m + Debt 12.6m - CCE 143.4m)
Interest Coverage Ratio = -12.41 (Ebit TTM -51.9m / Interest Expense TTM -4.18m)
EV/FCF = -1.17x (Enterprise Value 80.4m / FCF TTM -68.9m)
FCF Yield = -85.73% (FCF TTM -68.9m / Enterprise Value 80.4m)
FCF Margin = -6315 % (FCF TTM -68.9m / Revenue TTM 1.09m)
Net Margin = -4398 % (Net Income TTM -48.0m / Revenue TTM 1.09m)
Gross Margin = -1073 % ((Revenue TTM 1.09m - Cost of Revenue TTM 12.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 100.0%)
Tobins Q-Ratio = 0.22 (Enterprise Value 80.4m / Total Assets 372.7m)
Interest Expense / Debt = -33.16% (Interest Expense -4.18m / Debt 12.6m)
Taxrate = -0.37% (negative due to tax credits) (287.0k / -77.1m)
NOPAT = -52.1m (EBIT -51.9m * (1 - -0.37%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.67 (Total Current Assets 147.3m / Total Current Liabilities 13.8m)
Debt / Equity = -0.35 (negative equity) (Debt 12.6m / totalStockholderEquity, last quarter -35.8m)
Debt / EBITDA = 2.67 (negative EBITDA) (Net Debt -130.8m / EBITDA -49.0m)
Debt / FCF = 1.90 (negative FCF - burning cash) (Net Debt -130.8m / FCF TTM -68.9m)
Total Stockholder Equity = -16.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.59% (Net Income -48.0m / Total Assets 372.7m)
RoE = 286.6% (negative equity) (Net Income TTM -48.0m / Total Stockholder Equity -16.7m)
RoCE = 1254 % (out of range, set to none) (EBIT -51.9m / Capital Employed (Equity -16.7m + L.T.Debt 12.6m))
RoIC = 311.0% (negative operating profit) (NOPAT -52.1m / Invested Capital -16.7m)
WACC = 11.93% (E(211.1m)/V(223.8m) * Re(12.64%) + (debt cost/tax rate unavailable))
Discount Rate = 12.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 124.3%
Fair Price DCF = unknown (Cash Flow -68.9m)
EPS Correlation: -69.36 | EPS CAGR: -68.62% | SUE: -1.65 | # QB: 0
Revenue Correlation: -83.45 | Revenue CAGR: -67.31% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.85 | Chg30d=-0.002 | Revisions Net=+2 | Analysts=6
EPS next Year (2026-12-31): EPS=-2.58 | Chg30d=-0.710 | Revisions Net=-1 | Growth EPS=-33.7% | Growth Revenue=-73.5%
Additional Sources for RNAC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle